
MeiraGTx Holdings plc (NASDAQ:MGTX) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. (NYSE:LLY).
MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for Leber congenital amaurosis 4 (LCA4), an inherited eye disease that causes significant vision loss from birth.